Who is sponsoring NCT05625659?

NCT05625659 is sponsored by American College of Radiology.

What drugs are being tested in NCT05625659?

Interventions in NCT05625659: Dual-Energy Contrast-Enhanced Spectral Mammography (CESM).

What condition does NCT05625659 study?

NCT05625659 studies Breast Cancer.

Is NCT05625659 still recruiting?

NCT05625659 is currently recruiting now. Last updated 19 February 2026.

Last reviewed 2026-02-19 · How we verify

NCT05625659: CMIST

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts

Recruiting now NA Last updated 19 February 2026

What this trial tests

NA trial testing Dual-Energy Contrast-Enhanced Spectral Mammography (CESM) in Breast Cancer in 2,032 participants. Currently enrolling.

Timeline

24 March 2023

Primary endpoint
31 July 2027

31 July 2027

Quick facts

Lead sponsor	American College of Radiology
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	2,032
Start date	24 March 2023
Primary completion	31 July 2027
Estimated completion	31 July 2027
Sites	11 locations across Canada, United States

Drugs / interventions tested

Dual-Energy Contrast-Enhanced Spectral Mammography (CESM)

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

American College of Radiology

Who can join

Adults 45 to 74, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The over-arching goal of the Contrast-Enhanced Spectral Mammography Imaging Screening Trial (CMIST) is to determine if dual-energy contrast-enhanced spectral mammography (CESM) can detect more cancers with fewer false positives than digital breast tomosynthesis (DBT) in women with dense breasts. Aim 1: To evaluate the performance of CESM compared to DBT at baseline for breast-cancer screening in women with dense breasts. Aim 2: To evaluate the performance of CESM compared to DBT at the 1-year follow up for breast-cancer screening in women with dense breasts.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Addition of Contrast-enhanced Mammography to Tomosynthesis for Breast Cancer Detection in Women with a Personal History of Breast Cancer: Prospective TOCEM Trial Interim Analysis.
Berg WA, Berg JM, Bandos AI, Vargo A, et al · · 2024 · cited 13× · PMID 38687218 · DOI 10.1148/radiol.231991

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other American College of Radiology trials

Trials by the same sponsor.

NCT06055972 — Impact of Patient-Centered Approach for Communicating Coronary Calcium on Cardiovascular Health · NA · active not recruiting
NCT04426539 — New IDEAS: Imaging Dementia-Evidence for Amyloid Scanning Study · completed
NCT00794339 — Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05625659 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by American College of Radiology
Last refreshed: 19 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05625659.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing